The Goldman Sachs Group Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN - Free Report) had its target price reduced by The Goldman Sachs Group from $1,019.00 to $917.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company's stock.

Several other analysts have also issued reports on the stock. Wells Fargo & Company reduced their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a report on Friday, January 10th. Sanford C. Bernstein lowered their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. Bernstein Bank cut their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Canaccord Genuity Group cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, December 17th. Finally, Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target for the company. One analyst has rated the stock with a sell rating, six have given a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $963.56.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded up $13.88 on Monday, hitting $563.16. The company's stock had a trading volume of 827,663 shares, compared to its average volume of 712,904. The company has a market capitalization of $61.57 billion, a price-to-earnings ratio of 14.71, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals has a 1 year low of $525.99 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm has a fifty day moving average price of $645.94 and a 200-day moving average price of $740.52.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $11.86 earnings per share. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.63%. Regeneron Pharmaceuticals's payout ratio is 2.30%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Pamalican Asset Management Ltd bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $4,915,000. Intact Investment Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $356,000. Principal Financial Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after buying an additional 2,828 shares in the last quarter. Rhenman & Partners Asset Management AB grew its stake in Regeneron Pharmaceuticals by 11.4% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock valued at $30,956,000 after acquiring an additional 4,457 shares in the last quarter. Finally, Fagan Associates Inc. increased its stake in Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock valued at $9,205,000 after buying an additional 3,832 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.